Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects
Sponsor: 1ST Biotherapeutics, Inc.
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled study consisting of SAD and MAD investigation at a single clinical trial center conducted in healthy adult male subjects assessing the safety, tolerability, PK, and PD of oral FB-101 administration. Up to 72 healthy adult male subjects will be enrolled. Additional subjects may be enrolled (8 subjects per cohort) if it is deemed appropriate following review (e.g., in the circumstances where a dose level is repeated, or an intermediate dose is conducted or to add another dose level(s) (higher than those planned)).
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects
Key Details
Gender
MALE
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2025-11
Completion Date
2027-06
Last Updated
2025-08-17
Healthy Volunteers
Yes
Conditions
Interventions
FB-101
FB-101 10mg
Placebo for FB-101
Placebo for FB-101
Locations (1)
Seoul National University Hospital
Seoul, South Korea